110 related articles for article (PubMed ID: 2043724)
1. Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.
Wikberg T; Taskinen J
J Pharm Biomed Anal; 1991; 9(1):59-64. PubMed ID: 2043724
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.
Karlsson M; Wikberg T
J Pharm Biomed Anal; 1992 Aug; 10(8):593-600. PubMed ID: 1463794
[TBL] [Abstract][Full Text] [Related]
3. Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.
Wikberg T; Taskinen J
Drug Metab Dispos; 1993; 21(2):325-33. PubMed ID: 8097704
[TBL] [Abstract][Full Text] [Related]
4. Determination of nitecapone and (13C6)nitecapone in human plasma by gas chromatography/mass spectrometry.
Ottoila P; Pakkala E; Karlsson C; Taskinen J
Biol Mass Spectrom; 1991 Dec; 20(12):771-6. PubMed ID: 1812986
[TBL] [Abstract][Full Text] [Related]
5. Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile.
Wikberg T; Vuorela A
Eur J Drug Metab Pharmacokinet; 1994; 19(2):125-35. PubMed ID: 8001593
[TBL] [Abstract][Full Text] [Related]
6. Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine.
Taskinen J; Wikberg T; Ottoila P; Kanner L; Lotta T; Pippuri A; Bäckström R
Drug Metab Dispos; 1991; 19(1):178-83. PubMed ID: 1673395
[TBL] [Abstract][Full Text] [Related]
7. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
[TBL] [Abstract][Full Text] [Related]
8. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.
Schultz E; Tarpila S; Bäckström AC; Gordin A; Nissinen E; Pohto P
Eur J Clin Pharmacol; 1991; 40(6):577-80. PubMed ID: 1884738
[TBL] [Abstract][Full Text] [Related]
10. The equine metabolism of the catechol-O-methyltransferase enzyme inhibitor nitecapone.
Stanley S; Deng D; Van den Berg K; Foo HC
Drug Test Anal; 2022 May; 14(5):929-935. PubMed ID: 34545698
[TBL] [Abstract][Full Text] [Related]
11. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
[TBL] [Abstract][Full Text] [Related]
12. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
[TBL] [Abstract][Full Text] [Related]
13. Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.
Lehtonen P; Lehtinen S; Mälkki-Laine L; Wikberg T
J Chromatogr A; 1999 Mar; 836(1):173-88. PubMed ID: 10220913
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry.
Pang S; Zheng N; Felix CA; Scavuzzo J; Boston R; Blair IA
J Mass Spectrom; 2001 Jul; 36(7):771-81. PubMed ID: 11473400
[TBL] [Abstract][Full Text] [Related]
15. COMT inhibition with nitecapone does not affect the tyramine pressor response.
Sundberg S; Gordin A
Br J Clin Pharmacol; 1991 Jul; 32(1):130-2. PubMed ID: 1888633
[TBL] [Abstract][Full Text] [Related]
16. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection.
Timm U; Erdin R
J Chromatogr; 1992 Feb; 593(1-2):63-8. PubMed ID: 1639913
[TBL] [Abstract][Full Text] [Related]
17. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant properties of nitecapone (OR-462).
Suzuki YJ; Tsuchiya M; Safadi A; Kagan VE; Packer L
Free Radic Biol Med; 1992 Nov; 13(5):517-25. PubMed ID: 1334029
[TBL] [Abstract][Full Text] [Related]
19. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
[TBL] [Abstract][Full Text] [Related]
20. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury.
Haramaki N; Stewart DB; Aggarwal S; Kawabata T; Packer L
Biochem Pharmacol; 1995 Sep; 50(6):839-43. PubMed ID: 7575646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
